Burlington, NJ, United States of America

Brian T Campbell

This inventor holds 17 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 9 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Ambit Biosciences Corporation, Merck + Co., Inc.. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brian T Campbell. Retrieved from https://idiyas.com/inventor/brian-t-campbell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 2)

% Patents Active = 52.9

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 10)

Average Co-Inventor Count = 8.9

ph-index = 4

Forward Citations = 52(Granted Patents)

Location History:

San Diego, CA (US) (2006 - 2011)
Burlington, NY (US) (2016)
Burlington, NJ (US) (2013 - 2018)
Bensalem, PA (US) (2016 - 2021)
Souderton, PA (US) (2022)

Company Filing History:

9 out of 2,405

Merck Sharp + Dohme Corp.

patents

5 out of 39

Ambit Biosciences Corporation

Years Active: 2006-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331022 - Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors (2025-06-17),

2. 11332463 - Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors (2022-05-17),

3. 11026958 - Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors (2021-06-08),

4. 10065945 - Isoquinoline derivatives as MGAT2 inhibitors (2018-09-04),

5. 10053430 - RAF kinase modulator compounds and methods of use thereof (2018-08-21),

6. 9926285 - Allosteric modulators of nicotinic acetylcholine receptors (2018-03-27),

7. 9840481 - Allosteric modulators of nicotinic acetylcholine receptors (2017-12-12),

8. 9796733 - Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators (2017-10-24),

9. 9730937 - RAF kinase modulator compounds and methods of use thereof (2017-08-15),

10. 9453038 - Glucokinase activator compounds, compositions containing such compounds, and methods of treatment (2016-09-27),

11. 9320739 - RAF kinase modulator compounds and methods of use thereof (2016-04-26),

12. 8969587 - RAF kinase modulator compounds and methods of use thereof (2015-03-03),

13. 8618289 - RAF kinase modulator compounds and methods of use thereof (2013-12-31),

14. 7910561 - Inhibitors of Akt activity (2011-03-22),

15. 7465730 - [object Object] (2008-12-16),

Title: The Innovative Contributions of Brian T. Campbell

Introduction: Brian T. Campbell, an esteemed inventor based in Burlington, NJ, has made significant strides in the field of pharmacology with a remarkable portfolio of 16 patents. His innovative work primarily focuses on developing allosteric modulators of nicotinic acetylcholine receptors, which hold promise for treating various central nervous system disorders.

Latest Patents: Among Brian’s latest patents, two notable inventions stand out. The first patent describes spiropiperidine allosteric modulators of nicotinic acetylcholine receptors. This invention relates to compounds effective in modulating the α7 nAChR, with potential applications in preventing, treating, or ameliorating diseases such as cognitive impairments in Alzheimer’s disease, Parkinson’s disease, schizophrenia, L-DOPA induced dyskinesia, and inflammation. The second patent features substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors. Similar to the first patent, this invention aims to address multiple central nervous system disorders, further underscoring his commitment to enhancing therapeutic options for patients.

Career Highlights: Throughout his career, Brian T. Campbell has made notable contributions while working with renowned companies such as Merck Sharp & Dohme Corporation and Ambit Biosciences Corporation. His commitment to research and development has led to innovations with far-reaching impacts on healthcare.

Collaborations: Brian has collaborated with a number of talented professionals, including Sunny Abraham and Shripad S. Bhagwat. These collaborations have likely enriched his research efforts and facilitated knowledge exchange that drives innovation forward.

Conclusion: Brian T. Campbell's inventive prowess has positioned him as a key contributor to advancements in the treatment of central nervous system disorders. With a robust portfolio of patents and a background in influential companies, his work continues to pave the way for innovative therapies that enhance patient care and quality of life.

Profile summary based on public USPTO records.